The AD/PD Alzheimer Disease and Parkinson Disease Conference features presentations related to the latest breakthroughs in translational research, drug development, early diagnosis, treatment, and clinical trials in Alzheimer, Parkinson, and other related neurological disorders.
AC Immune SA Shares Phase 2 VacSYn Trial Update for ACI-7104.056 in Parkinson Disease
Published: March 28th 2024 | Updated: May 23rd 2024At AD/PD 2024, AC Immune SA presented an update on the company's phase 2 VacSYn trial assessing ACI-7104.056, an anti-α-synuclein active immunotherapy, for patients with Parkinson disease.